Загрузка...
A phase II trial with rosiglitazone in liposarcoma patients
Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte differentiation. One study has shown clinical activity of troglitazone treatment in liposarcoma patients. We sought to find further evidence for this...
Сохранить в:
Главные авторы: | , , , , , |
---|---|
Формат: | Artigo |
Язык: | Inglês |
Опубликовано: |
Nature Publishing Group
2003
|
Предметы: | |
Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2394353/ https://ncbi.nlm.nih.gov/pubmed/14562008 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601306 |
Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|